Analysts forecast that Stryker Co. (NYSE:SYK) will report $3.20 billion in sales for the current fiscal quarter, Zacks reports. Eleven analysts have issued estimates for Stryker’s earnings, with estimates ranging from $3.15 billion to $3.24 billion. Stryker reported sales of $2.96 billion in the same quarter last year, which indicates a positive year-over-year growth rate of 8.1%. The company is scheduled to announce its next earnings report after the market closes on Thursday, April 26th.
On average, analysts expect that Stryker will report full year sales of $3.20 billion for the current fiscal year, with estimates ranging from $13.32 billion to $13.67 billion. For the next fiscal year, analysts anticipate that the firm will report sales of $14.40 billion per share, with estimates ranging from $14.22 billion to $14.56 billion. Zacks’ sales averages are an average based on a survey of analysts that that provide coverage for Stryker.
Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $1.96 EPS for the quarter, beating the consensus estimate of $1.95 by $0.01. The business had revenue of $3.47 billion for the quarter, compared to the consensus estimate of $3.42 billion. Stryker had a net margin of 8.20% and a return on equity of 24.56%. The business’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.78 EPS.
In other news, VP William E. Berry, Jr. sold 1,306 shares of the stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $164.42, for a total value of $214,732.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Katherine Ann Owen sold 3,700 shares of the stock in a transaction dated Monday, March 5th. The shares were sold at an average price of $161.66, for a total transaction of $598,142.00. Following the completion of the sale, the vice president now owns 7,596 shares of the company’s stock, valued at $1,227,969.36. The disclosure for this sale can be found here. Insiders have sold 142,489 shares of company stock valued at $23,488,485 over the last 90 days. 7.40% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the company. San Francisco Sentry Investment Group CA grew its holdings in shares of Stryker by 47.8% in the third quarter. San Francisco Sentry Investment Group CA now owns 1,005 shares of the medical technology company’s stock valued at $143,000 after purchasing an additional 325 shares during the period. Advisor Partners LLC grew its holdings in shares of Stryker by 7.2% in the fourth quarter. Advisor Partners LLC now owns 4,827 shares of the medical technology company’s stock valued at $779,000 after purchasing an additional 326 shares during the period. Putnam FL Investment Management Co. grew its holdings in shares of Stryker by 0.7% in the fourth quarter. Putnam FL Investment Management Co. now owns 44,867 shares of the medical technology company’s stock valued at $6,947,000 after purchasing an additional 332 shares during the period. Founders Capital Management LLC grew its holdings in shares of Stryker by 1.4% in the fourth quarter. Founders Capital Management LLC now owns 25,790 shares of the medical technology company’s stock valued at $3,993,000 after purchasing an additional 350 shares during the period. Finally, LS Investment Advisors LLC grew its holdings in shares of Stryker by 3.6% in the fourth quarter. LS Investment Advisors LLC now owns 10,249 shares of the medical technology company’s stock valued at $1,587,000 after purchasing an additional 354 shares during the period. Institutional investors and hedge funds own 75.71% of the company’s stock.
Shares of SYK stock traded up $2.95 during trading hours on Wednesday, hitting $160.92. The company’s stock had a trading volume of 1,583,893 shares, compared to its average volume of 1,165,640. The company has a market capitalization of $60,287.39, a P/E ratio of 24.80, a price-to-earnings-growth ratio of 2.31 and a beta of 0.70. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.29 and a quick ratio of 1.59. Stryker has a 12-month low of $129.82 and a 12-month high of $170.00.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, April 30th. Shareholders of record on Thursday, March 29th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 1.17%. The ex-dividend date is Wednesday, March 28th. Stryker’s dividend payout ratio is presently 28.97%.
TRADEMARK VIOLATION NOTICE: “Stryker Co. (SYK) Expected to Post Quarterly Sales of $3.20 Billion” was first posted by WKRB News and is the property of of WKRB News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://www.wkrb13.com/2018/03/31/stryker-co-syk-expected-to-post-quarterly-sales-of-3-20-billion.html.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.